Issue

Vol. 26 No. 18 (2014): Vol 26 Issue 18

Copyright (c) 2014 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

in silico Binding Mode Analysis (Molecular Docking Studies) and Absorption, Distribution, Metabolism and Excretion Prediction of Some Novel Inhibitors of Aurora Kinase A in Clinical Trials

https://doi.org/10.14233/ajchem.2014.17175
Pran Kishore Deb
Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), 126, JalanJalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
Dina El-Rabie
Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), 126, JalanJalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
Ahmad Junaid
Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), 126, JalanJalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
Jeyashanthini A/P Nalaiya
Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), 126, JalanJalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
Lim Chee Siong
Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), 126, JalanJalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
Kulasekar A/L Kulasingam
Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), 126, JalanJalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
Mallikarjuna Rao Pichika
Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), 126, JalanJalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia

Corresponding Author(s) : Pran Kishore Deb

prankishore@imu.edu.my; prankishore1@gmail.com

Asian Journal of Chemistry, Vol. 26 No. 18 (2014): Vol 26 Issue 18

Abstract

The inhibition of Aurora kinase A is considered to be one of the most promising therapeutic targets for the treatment of cancer. To gain insight into the structural requirements for effective binding and inhibiting the enzyme Aurora kinase A, molecular docking study was carried out by using the potent Aurora kinase A inhibitors (AKAIs) that are currently under clinical trials by employing Glide module of Schrodinger software. Prime MM-GBSA approach was used to study the free energy of binding of these AKIs with the enzyme. Binding mode analysis indicated that a molecule should occupy both ATP binding site (forming essential hydrogen bonding interaction with crucial amino acid residue such as Ala213) as well as allosteric binding cleft (forming hydrogen bonding interaction with amino acid residues Lys162 and Glu181) for exhibiting optimum affinity as well as selectivity towards Aurora kinase A. Further, ADME properties of these study compounds were calculated to get better insight into the physicochemical requirements for effective binding of ligands with Aurora kinase A and also to evaluate their drug-like acceptability which was found to be in the ranges predicted by QikProp module of Schrodinger software for 95 % of known oral drugs. Results confirm the potential of the study which could be useful for the design of new potent inhibitors of Aurora kinase A as possible anticancer agents.

Keywords

Aurora kinase A inhibitors Docking studies in silico ADME prediction
Kishore Deb, P., El-Rabie, D., Junaid, A., A/P Nalaiya, J., Chee Siong, L., A/L Kulasingam, K., & Rao Pichika, M. (2014). in silico Binding Mode Analysis (Molecular Docking Studies) and Absorption, Distribution, Metabolism and Excretion Prediction of Some Novel Inhibitors of Aurora Kinase A in Clinical Trials. Asian Journal of Chemistry, 26(18), 6221–6226. https://doi.org/10.14233/ajchem.2014.17175
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. J. Fu, M. Bian, Q. Jiang and C. Zhang, Mol. Cancer Res., 5, 1 (2007); doi:10.1158/1541-7786.MCR-06-0208.
  2. O. Gautschi, J. Heighway, P.C. Mack, P.R. Purnell, P.N. Lara and D.R. Gandara, Clin. Cancer Res., 14, 1639 (2008); doi:10.1158/1078-0432.CCR-07-2179.
  3. M. Carmena and W.C. Earnshaw, Mol. Cell. Biol., 4, 842 (2003); doi:10.1038/nrm1245.
  4. H.L. Chen, C.J. Tang, C.Y. Chen and T.K. Tang, J. Biomed. Sci., 12, 297 (2005); doi:10.1007/s11373-005-0980-0.
  5. S. Sen, H.R.A. Zhou and R.A. White, Oncogene, 14, 2195 (1997); doi:10.1038/sj.onc.1201065.
  6. T. Takahashi, M. Futamura, N. Yoshimi, J. Sano, M. Katada, Y. Takagi, M. Kimura, T. Yoshioka, Y. Okano and S. Saji, J. Cancer Res., 91, 1007 (2000); doi:10.1111/j.1349-7006.2000.tb00878.x.
  7. D. Li, J. Zhu, P.F. Firozi, J.L. Abbruzzese and D.B. Evans, Clin. Cancer Res., 9, 991 (2003).
  8. T.M. Gritsko, D. Coppola, J.E. Paciga, L. Yang and M. Sun, Clin. Cancer Res., 9, 1420 (2003).
  9. C. Sakakura, A. Hagiwara, R. Yasuoka, Y. Fujita, M. Nakanishi, K. Masuda, K. Shimomura, Y. Nakamura, J. Inazawa, T. Abe and H. Yamagishi, Br. J. Cancer, 84, 824 (2001); doi:10.1054/bjoc.2000.1684.
  10. S. Ulisse, E. Baldini, M. Toller, J.G. Delcros, A. Gueho, F. Curcio, E. De Antoni, L. Giacomelli, F.S. Ambesi-Impiombato, S. Bocchini, M. D’Armiento and Y. Arlot-Bonnemains, Endocr. Relat. Cancer, 14, 827 (2007); doi:10.1677/ERC-07-0053.
  11. R. Reiter, P. Gais, U. Jutting, M.K. Steuer-Vogt and A. Pickhard, Clin. Cancer Res., 12, 5136 (2006); doi:10.1158/1078-0432.CCR-05-1650.
  12. Q. Liu, S. Kaneko, L. Yang, R.I. Feldman, S.V. Nicosia, J. Chen and J.Q. Cheng, J. Biol. Chem., 279, 52175 (2004); doi:10.1074/jbc.M406802200.
  13. F. Robert, H. Hurwitz, C.F. Verschraegen, R. Verschraegen, R. Advani, C. Berman, P. Taverna and M. Evanchik, ASCO Annual Meeting, Orlando, FL, USA, Abstract 14642 (2009).
  14. S. Wang, C.A. Midgley, F. Scaerou, J.B. Grabarek, G. Griffiths, W. Jackson, G. Kontopidis, S.J. McClue, C. McInnes, C. Meades, M. Mezna, A. Plater, I. Stuart, M.P. Thomas, G. Wood, R.G. Clarke, D.G. Blake, D.I. Zheleva, D.P. Lane, R.C. Jackson, D.M. Glover and P.M. Fischer, J. Med. Chem., 53, 4367 (2010); doi:10.1021/jm901913s.
  15. C. Soncini, P. Carpinelli, L. Gianellini, D. Fancelli, P. Vianello, L. Rusconi and P. Storici, Clin. Cancer Res., 12, 4080 (2006); doi:10.1158/1078-0432.CCR-05-1964.
  16. R. Paquette, N. Shah, C. Sawyers, G. Martinelli, J. Nicoll, M. Chalukya, G. Locatelli, L. Capolongo, J. Moll, S. Comis and B. Laffranchi, Haematol. Meet. Rep., 2, 92 (2008).
  17. R.B. Cohen, S.F. Jones, C. Aggarwal, M. von Mehren, J. Cheng, D.R. Spigel, F.A. Greco, M. Mariani, M. Rocchetti, R. Ceruti, S. Comis, B. Laffranchi, J. Moll and H.A. Burris, Clin. Cancer Res., 15, 6694 (2009); doi:10.1158/1078-0432.CCR-09-1445.
  18. M. Payton, T.L. Bush, G. Chung, B. Ziegler, P. Eden, P. McElroy, S. Ross, V.J. Cee, H.L. Deak, B.L. Hodous, H.N. Nguyen, P.R. Olivieri, K. Romero, L.B. Schenkel, A. Bak, M. Stanton, I. Dussault, V.F. Patel, S. Geuns-Meyer, R. Radinsky and R.L. Kendall, Cancer Res., 70, 9846 (2010); doi:10.1158/0008-5472.CAN-10-3001.
  19. Maestro version 9.4, and Glide v5.9, Schrödinger, LLC, New York, NY, (2013-1).
  20. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis and P.S. Shenkin, J. Med. Chem., 47, 1739 (2004); doi:10.1021/jm0306430.
  21. M.S. Coumar, C.-Y. Chu, C.-W. Lin, H.-Y. Shiao, Y.-L. Ho, R. Reddy, W.-H. Lin, C.-H. Chen, Y.-H. Peng, J.-S. Leou, T.-W. Lien, C.-T. Huang, M.-Y. Fang, S.-H. Wu, J.-S. Wu, S.K. Chittimalla, J.-S. Song, J.T.-A. Hsu, S.-Y. Wu, C.-C. Liao, Y.-S. Chao and H.-P. Hsieh, J. Med. Chem., 53, 4980 (2010); doi:10.1021/jm1000198.
  22. G.A. Kaminski, R.A. Friesner, J. Tirado-Rives and W.L. Jorgensen, J. Phys. Chem., 105, 6474 (2001); doi:10.1021/jp003919d.
  23. Prime, version 3.2, Schrodinger, LLC, New York, NY (2013).
  24. QikProp, version 3.6, Schrodinger, LLC, New York, NY (2013-1).
  25. C.A. Lipinski, F. Lombardo, B.W. Dominy and P.J. Feeney, Adv. Drug Deliv. Rev., 46, 3 (2001); doi:10.1016/S0169-409X(00)00129-0.
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 0 Download : 1